Achieve announces allowance of u.s. patents for dosing and administration of cytisinicline for the treatment and prevention of addiction

Seattle, wa and vancouver, bc / accesswire / june 3, 2021 / achieve life sciences, inc. (nasdaq:achv), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the united states patent and trademark office has allowed u.s. patent application no. 16/993,522 (the ‘522 application) and u.s. patent application no.
ACHV Ratings Summary
ACHV Quant Ranking